Inventiva (NASDAQ:IVA) Price Target Raised to $18.00

Inventiva (NASDAQ:IVA) had its target price boosted by Truist Financial from $13.00 to $18.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other brokerages have also recently weighed in on IVA. Guggenheim upped their price target on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research note on Friday, July 17th. They issued an “overweight” rating on the stock. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Inventiva in a report on Wednesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $15.86.

Inventiva Price Performance

NASDAQ IVA opened at $3.56 on Friday. Inventiva has a 1-year low of $3.11 and a 1-year high of $7.98. The stock’s 50 day moving average is $4.33 and its two-hundred day moving average is $4.65.

Inventiva (NASDAQ:IVA) last issued its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The firm had revenue of $0.75 million during the quarter. Research analysts predict that Inventiva will post -0.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inventiva

Institutional investors have recently bought and sold shares of the business. Engineers Gate Manager LP boosted its stake in Inventiva by 155.5% in the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock worth $269,000 after purchasing an additional 43,280 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Inventiva in the fourth quarter valued at $603,000. Seven Fleet Capital Management LP acquired a new stake in shares of Inventiva in the first quarter valued at $1,111,000. Eventide Asset Management LLC bought a new position in shares of Inventiva in the fourth quarter valued at about $1,155,000. Finally, Propel Bio Management LLC bought a new position in shares of Inventiva in the fourth quarter valued at about $4,650,000. Institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Dijon, France. The company develops oral small-molecule therapies for chronic metabolic and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an investigational pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.